Compare · Nootropic peptide
Cerebrolysin vs Dihexa
Both are nootropic peptide compounds. Here's how they line up on the evidence — graded the same way.
| Cerebrolysin | Dihexa | |
|---|---|---|
| Evidence | 6/10 | 3/10 |
| Class | Nootropic peptide | Nootropic peptide |
| Summary | Cerebrolysin has more human trial data than most research peptides, yet its largest rigorous stroke trial was neutral and independent reviews find little benefit. | An angiotensin IV-derived oligopeptide studied in animals for synaptogenesis and cognition; it has never been tested in humans, and its foundational mechanism paper was retracted in 2025. |
| Full profile → | Full profile → |
Cerebrolysin
Cerebrolysin is one of the few compounds in the "nootropic peptide" (brain-boosting peptide) world that has actually been studied in a serious way. Most research peptides have very little human data. This one is different: it has a real history as a prescription drug in other countries, several…
Dihexa
Dihexa is a small peptide (a short chain of amino acids, the building blocks of proteins) made from a natural molecule called angiotensin IV. It got attention because of animal studies showing it could help neurons grow new connections and improve learning, along with a striking claim that it is…